Today, Cardiff Oncology Inc (NASDAQ: CRDF) Takes Center Stage

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Cardiff Oncology Inc is $256.86M. A total of 1.43 million shares were traded on the day, compared to an average of 1.90M shares.

In the most recent transaction, Levine James E. bought 2,752 shares of CRDF for 5.42 per share on Dec 17 ’24. After the transaction, the Chief Financial Officer now owns 65,316 company shares. In a previous transaction on Dec 18 ’24, Levine James E. bought 2,400 shares at 5.00 per share. CRDF shares that Chief Financial Officer owns now total 67,716.

Among the insiders who bought shares, Levine James E. acquired of 2,564 shares on Dec 16 ’24 at a per-share price of $3.83. This resulted in the Chief Financial Officer holding 62,564 shares of CRDF after the transaction. In another insider transaction, TANNENBAUM RENEE P bought 10,000 shares at $3.42 per share on Dec 12 ’24. Company shares held by the Director now total 20,000.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, CRDF has a high of $6.42 and a low of $1.41.

As of this writing, CRDF has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.2 per share and a lower estimate of -$0.29.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CRDF’s latest balance sheet shows that the firm has $140.82M in Cash & Short Term Investments as of fiscal 2021. There were $3.12M in debt and $6.56M in liabilities at the time. Its Book Value Per Share was $1.01, while its Total Shareholder’s Equity was $140.42M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRDF is Buy with a score of 5.00.

Most Popular

Related Posts